Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sutro Biopharma Inc.

www.sutrobio.com

Latest From Sutro Biopharma Inc.

Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies

Roivant will use the cash to fund other "Vants" that develop drugs or make the process more efficient. Also, Zealand launches its IPO, Apellis raises a $60m Series E and BioMarin tops recent offerings.

Financing Business Strategies

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

Celgene Revamps IO Deal With Emerging Biotech Sutro; Takeover Option Removed

Celgene and small Californian biotech Sutro have renovated their 2014 cancer drug discovery deal to grant Celgene worldwide rights to the first two products to emerge from the arrangement, and to lift restrictions on Sutro accessing public financial markets.

Deals ImmunoOncology

Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?

With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.

BioPharmaceutical Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Fundamental Applied Biology Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sutro Biopharma Inc.
  • Senior Management
  • Willliam J Newell, CEO
    Edward C Albini, CFO
    Jeremy Bender, PhD, CBO
    Trevor Hallam, PhD, CSO
  • Contact Info
  • Sutro Biopharma Inc.
    Phone: (650) 392-8412
    310 Utah Ave.
    Ste. 150
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register